safety

Safety & Handling

Reviewed 2026-08-09·VALEN LABS editorial·Educational reference — not medical advice
ⓘ Educational reference for laboratory reconstitution and research only. Not medical advice, not dosing instructions for human use.

VALEN LABS — Peptide Safety & Compliance Knowledge Base

Version: 1.0 Date: 2026-08-09 Owner: VALEN LABS (research-peptide brand, EU + Serbia) Positioning: Research Use Only (RUO) — all products are laboratory research reagents. Not for human or animal consumption. Not approved as medicines, foods, or cosmetics by EMA, FDA, MHRA, Swissmedic, ALIMS (Serbia), or any other medicines authority.

How to use this document

This file is the internal safety knowledge base that powers VALEN LABS website content: product-page safety cards, the universal safety page, legal pages, and the responsible-sales policy. It is written for researchers and compliance staff, not as medical advice and not as patient-facing treatment information. Nothing here authorises, recommends, or implies any human use of any product. Every factual claim is sourced; the full URL list is in Section 7.

Accuracy note: Because most of these compounds have little or no human clinical data, the "side effects" below are a mix of (a) trial-reported adverse events for the exact compound, (b) class-level effects from related approved drugs, and (c) community/anecdotal reports clearly labelled as such. We never present anecdote as evidence. Where evidence is absent we say so.

1. SAFETY OVERVIEW & UNIVERSAL CAUTIONS

1.1 The single most important fact

None of the 14 SKUs in this catalogue is an approved medicine for the purposes VALEN LABS customers are interested in. The regulatory reality:

  • BPC-157, TB-500, CJC-1295, Ipamorelin, GHK-Cu, MOTS-c, Kisspeptin-10, NAD+, SS-31 (outside its narrow Barth-syndrome approval), GLOW, and Retatrutide are not approved for any human indication by the FDA or EMA. (Sources: Examine.com on BPC-157; USADA on MOTS-c; Drugs.com on Retatrutide; FDA compounding list on Kisspeptin-10/GHK-Cu.)
  • Tesamorelin (Egrifta) and SS-31 (elamipretide, Barth syndrome, 2025) are approved drugs only for narrow indications; every other use is off-label/investigational. (Sources: Drugs.com Tesamorelin; Empire Medical Training on SS-31.)
  • Tirzepatide (Mounjaro/Zepbound) and Semaglutide (Ozempic/Wegovy/Rybelsus) are approved drugs for diabetes and weight management. Any peptide-shop version sold as a research chemical is unlicensed and sits in the highest-scrutiny category at every regulator (see §5.3).
  • WADA bans essentially the entire "growth and repair" category (BPC-157, TB-500, CJC-1295, Ipamorelin, Tesamorelin, GHRPs, GLP-1s) for athletes under the 2026 Prohibited List, S2 — Peptide Hormones, Growth Factors, Related Substances, and Mimetics. (Source: Superpower CJC/ Ipamorelin guide; GlobalRPH; MDPI Tβ4 review.)

1.2 Universal cautions that apply to ALL 14 SKUs

These belong on every product page and in the site-wide safety banner. They are not compound- specific; they are inherent to buying injectable, unlicensed peptides online.

  1. No long-term human safety data. For most of these molecules, no completed clinical trials exist at all. Long-term effects (years) are unknown by definition. (Sources: Examine.com, USADA, ColumbiaDoctors, Guardian.)
  2. Injection = infection risk. Every product is injected (or reconstituted for injection). Infection, abscess, sepsis, allergic reaction, and dosing error are real risks of self-injection of unlicensed products. (Sources: Health Canada; Rite Aid; Healthymale.org.au.)
  3. Product quality is not guaranteed by any regulator. Gray-market vials can contain too much/too little/none of the active ingredient, unlisted ingredients, heavy metals, particles, and bacterial endotoxins. Third-party testing exists precisely because of this. (Sources: Health Canada; Finnrick; The Peptide List investigation; Janoshik via The Guardian.)
  4. Pregnancy & breastfeeding: do not use. Every source that addresses it contraindicates peptide use in pregnancy/breastfeeding — no adequate human data exists for any of these compounds in pregnancy. (Sources: Drugs.com Tesamorelin; MoonshotMP TB-500; Innerbody Tβ4.)
  5. Minors: research-only products are not for anyone under 18. Industry standard age gate is 18+ (EU/UK) or 21+ (US-facing stores). (Sources: CleanPeptides gate; Pure Health Peptides 21+; SwissChems 21+; SyntheVial Labs policy.)
  6. Active cancer or history of cancer — extreme caution / absolute contraindication for growth-promoting peptides. GH secretagogues, GHRH analogues, and angiogenesis-related peptides (BPC-157, TB-500) are contraindicated or strongly cautioned in active malignancy because GH/IGF-1 signalling and angiogenesis can in theory promote tumour growth. (Sources: Peptides Lab UK Tesamorelin; Innerbody CJC-1295; GlobalRPH BPC-157/TB-500; MoonshotMP.)
  7. No human dosing protocols from us. VALEN LABS publishes molecular research data only. "Dosing for humans" content is both medically irresponsible and legally hazardous (see §5.4).
  8. Blood-sugar effects. GH-raising peptides can worsen insulin resistance/glucose tolerance; GLP-1-class peptides can cause hypoglycaemia when combined with other glucose-lowering agents. (Sources: PLOS ONE Tesamorelin T2D trial; PMC GLP-1 safety review; Peptide Protocol Wiki.)
  9. Unknown drug interactions. For almost all of these compounds, formal interaction studies do not exist. "No data" must be stated as "no data", never as "safe".
  10. Endotoxin is invisible. A sterile-looking, HPLC-"99% pure" vial can still carry pyrogenic endotoxin. This is why we test and publish COAs (Section 4).

1.3 Universal who-should-not-use list (site-wide)

| Category | Rationale | Source | |---|---|---| | Pregnant / breastfeeding / trying to conceive | No safety data; hormonal/GH effects on foetus unacceptable | Drugs.com (Tesamorelin), MoonshotMP (TB-500), GlobalRPH | | Anyone under 18 | RUO products are for adult researchers; age gate industry standard | CleanPeptides, SwissChems, Pure Health Peptides | | Active cancer, recent cancer, unexplained lumps/masses | GH/IGF-1 and angiogenic signalling may in theory promote growth | Peptides Lab UK, Innerbody, GlobalRPH | | Pituitary disease / pituitary tumour / prior pituitary irradiation | GH-axis peptides act on the pituitary | Drugs.com (Tesamorelin) | | Known allergy to the compound or its excipients | Anaphylaxis risk | Drugs.com (Tesamorelin), Synapse | | People with bleeding disorders or on anticoagulants | Injections + theoretical bleeding-risk modulation | Ubie Health (BPC-157), GlobalRPH | | Diabetics / insulin-resistant, esp. with glucose-lowering medication | GH peptides worsen glucose control; GLP-1s add hypoglycaemia risk | PLOS ONE, PMC GLP-1 review | | Anyone buying for self-administration | This is exactly the use our RUO framing does NOT permit | Section 5 |

2. PER-PEPTIDE SAFETY CARDS (14 SKUs)

Format per card: identity → evidence base → side effects table → serious/theoretical risks → contraindications → interactions → what we publish on the product page.

2.1 GLOW (blend)

Identity: Blend, composition varies by vendor. Industry-standard "GLOW" = BPC-157 + TB-500 (Thymosin β4 fragment) + GHK-Cu, marketed for skin/joint/recovery research. VALEN LABS must publish the exact per-vial composition of our blend; "GLOW" alone is not a defined substance.

Evidence base: No clinical trial of "GLOW" as such exists. Safety = combination of the three components' profiles (see cards 2.13 BPC-157, 2.12 TB-500, 2.8 GHK-Cu).

Safety summary table (blend-level):

| Domain | Finding | |---|---| | Common side effects (reported/anecdotal) | Injection-site reactions, flushing, transient nausea, headache, fatigue, copper-related skin effects if applied topically | | Serious risks | Same as components: theoretical pro-angiogenic/tumour-promotion concern (BPC-157, TB-500); immunogenicity risk of injectable GHK-Cu (FDA) | | Contraindications | Pregnancy/breastfeeding; active cancer; copper-metabolism disorders; bleeding disorders | | Interactions | No interaction data exists for the blend; treat as the union of component interactions (anticoagulants, glucose-lowering agents) |

Key risk note: Blend products multiply the unknowns — three actives, three impurity profiles, no blend-level data. Requires the most rigorous COA of any SKU.

Sources: Rite Aid (BPC-157), MoonshotMP (TB-500), First Compounding Pharmacy (GHK-Cu), Superpower informed-consent (GHK-Cu FDA immunogenicity note).

2.2 SS-31 (Elamipretide)

Identity: Mitochondria-targeted tetrapeptide (cardiolipin-binding); developed by Stealth BioTherapeutics as elamipretide/Bendavia/MTP-131. Reported to have received FDA approval in 2025 for Barth syndrome, a rare mitochondrial disorder — the first mitochondrial-targeted peptide to reach approval (per Empire Medical Training and Biomeme).

Evidence base: Strongest trial dataset of any mitochondrial peptide: Phase 2/3 programs in primary mitochondrial myopathy (MMPOWER series), Barth syndrome (TAZPOWER), heart failure, AMD (ReCLAIM), STEMI (EMBRACE-STEMI). Long-term daily subcutaneous dosing for up to 168 weeks studied.

Side effects table:

| Effect | Frequency/Notes | Source | |---|---|---| | Injection-site reactions (erythema, induration, pruritus, pain, haemorrhage) | Most frequent AE in trials | The Peptide Catalog; PMC9192202 | | Injection-site pruritus | Reported up to ~47% in one kidney-disease review; mostly mild | PMC9192202 | | Injection-site pain / urticaria / irritation | 20% / 20% / 10% in same review; mild | PMC9192202 | | Dizziness, headache | Observed; no serious AEs or fatalities in reviewed trials | PMC9192202 | | Systemic serious AEs | Not reported in reviewed trials | PMC9192202; Neurology dose-escalation trial |

Serious/theoretical risks: Low systemic toxicity in trial populations. No data for longevity/"anti-ageing" use outside the studied indications and doses — the common grey-market use pattern has no comparable safety dataset (Empire Medical Training).

Contraindications: Pregnancy/breastfeeding (no data); hypersensitivity to the peptide; any use outside approved indication should be treated as investigational.

Interactions: No clinically relevant interactions established. Theoretical: agents acting on mitochondrial function/oxidative phosphorylation.

What we publish: Trial-derived AE table, statement that grey-market dosing has no safety data, "not approved for longevity use" line.

Sources: empiremedicaltraining.com (SS-31); thepeptidecatalog.com/articles/ss-31-side-effects; PMC9192202 (SS-31 kidney review); Neurology.org dose-escalation trial; biomeme.com (SS-31 evidence score); PMC11816484 (elamipretide review).

2.3 Kisspeptin-10 (KP-10)

Identity: N-terminal decapeptide fragment of kisspeptin; activates GPR54 (KISS1R) → GnRH release → LH/FSH. Research interest: reproductive physiology, psychosexual function, metabolic effects.

Evidence base: Decent early human data for an unapproved peptide: single IV/subcutaneous doses in >100 healthy volunteers and patient cohorts, well tolerated with no serious AEs; RCTs in women with hypoactive sexual desire disorder (JAMA Netw Open 2022) and men (JAMA Psychiatry 2023) report no significant side effects, no BP/HR changes. Animal tox: no toxicity in dogs at up to 1,000 µg/kg IV × 14 days.

Side effects table:

| Effect | Frequency/Notes | Source | |---|---|---| | Serious adverse events | None reported in published human studies to date | NCT04648969 informed consent; PMC9898824 | | Injection-site reactions | Rare, minor (redness/discomfort) | YouTube/clinical review (anecdotal-leaning), Peptides Lab UK | | Transient mood/anxiety changes | Theoretically possible via hormonal shifts; not observed in HSDD RCT | PMC9898824 (no mood/anxiety difference) | | Ovarian hyperstimulation (theoretical, women) | Upstream GnRH pathway; considered less likely than with HCG | Clinical review |

Serious/theoretical risks: FDA (2023) lists Kisspeptin-10 among bulk drug substances that may present significant safety risks in compounding: "Compounded drugs containing Kisspeptin-10 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA has no, or only limited, safety-related information for the proposed routes of administration."

Contraindications: Pregnancy/breastfeeding (hormonal; trials exclude pregnant women); hormone-sensitive cancers (e.g., some reproductive cancers — GnRH pathway activation); taking hormone-affecting medications (trial exclusion).

Interactions: GnRH-agonist/antagonist pathway overlap; sex-hormone therapies; any medication affecting the HPG axis. No formal interaction studies.

What we publish: Trial-tolerability summary + FDA compounding-risk quote + exclusion criteria from the Kisspeptin trial ICF (hypertension, hormone medications, pregnancy).

Sources: FDA bulk-drug-substances list; clinicaltrials.gov NCT04648969 ICF; PMC9898824 (Kisspeptin sexual-brain-processing trial); JAMA Netw Open 2797718; Peptides Lab UK; redfoxpeptides.is.

2.4 NAD+ (and precursors NMN/NR/NAM)

Identity: Nicotinamide adenine dinucleotide; the oxidised form injected IV/IM/sub-Q in "NAD+ therapy". Precursors NMN, NR, nicotinamide (NAM) are the oral forms.

Evidence base: NAD+ precursors have decades of use and human trials (weeks–months duration); direct NAD+ injection/IV has less formal trial evidence but a long clinic case-history.

Side effects table:

| Effect | Frequency/Notes | Source | |---|---|---| | Flushing, warmth, chest tightness, nausea (IV, fast infusion) | Common, dose-rate dependent — resolves when infusion slowed; NOT an allergic reaction | Get Healthspan; Jana Healthcare | | Injection-site pain/redness/bruising (sub-Q/IM) | Common, minor, transient | Helimeds; Goldman Labs | | Headache, fatigue, dizziness | Common, transient | Goldman Labs; Jana | | Transient liver-enzyme elevation | Reported in trials, short-term; resolve | Jana; NAD.com | | GI upset (oral precursors) | Nausea, bloating, loose stools, belching | Jana; Perfectb; NAD.com | | Transient rise in hs-CRP (~70% of IV patients) | Inflammatory marker bump, not clinically significant per sources | Goldman Labs | | Sleep disturbance / vivid dreams (NMN/NR, evening dosing) | Reported | Perfectb; Hubmed |

Serious/theoretical risks: High-dose NAM (≥1 g/day) can raise liver enzymes, decrease insulin sensitivity; very high doses (≥3 g/day) linked to reversible hepatotoxicity in animal models. Rare case-report events (allergic reactions, phlebitis, electrolyte imbalance) mostly tied to non-pharmaceutical-grade preparations. Caution groups: liver disease, diabetes/impaired glucose, gout, low blood pressure, GI ulcers, kidney disease, bleeding disorders (Helimeds). "Boosting NAD+ does not cause cancer" per NAD.com, but NAD+-boosting may feed inflammation-related senescence pathways — an open research question.

Contraindications: Pregnancy/breastfeeding (no adequate data); known sensitivity to niacin forms; the caution groups above.

Interactions: Alcohol (liver load, theoretical); drugs affecting liver enzymes; theoretical AMPK-pathway overlaps with metformin (shared target space); vasodilators (additive flushing/BP).

What we publish: Route-by-route AE table; "no long-term (>1 yr) data" statement; caution list.

Sources: janahealthcare.com; helimeds.com; hubmeded.com; gethealthspan.com; goldmanlaboratories.com; nad.com; ScienceDirect NMN review.

2.5 MOTS-c

Identity: Mitochondrial-derived peptide (16 aa), encoded by mitochondrial 12S rRNA; metabolic/ exercise research interest (AMPK pathway, glucose homeostasis, ageing).

Evidence base: No completed clinical trials of MOTS-c itself in humans. One Phase 1a/1b trial of the MOTS-c analogue CB4211 (obesity + fatty liver) reported safe and well tolerated with no serious AEs, though persistent injection-site reactions were common; a clinical trial of native MOTS-c for insulin sensitivity is registered (NCT07505745).

Side effects table (largely self-reported grey-market data — label as such):

| Effect | Frequency/Notes | Source | |---|---|---| | Increased heart rate / palpitations | Reported among online self-experimenters; no trial confirmation | USADA; BSCG; ADDF | | Injection-site irritation | Reported; also seen with CB4211 analog | USADA; ADDF | | Sleep disturbance / insomnia | Reported | USADA; BSCG | | Fever | Reported | USADA; BSCG | | Headache, flushing, fatigue, mild GI (nausea, stomach discomfort) | Reported | Innerbody |

Serious/theoretical risks: USADA: "Currently it is unknown under what conditions (if any) it is safe to use MOTS-c because there are no completed clinical trials." FDA has clarified MOTS-c is unlawful to use in compounding. Theoretical: interaction with folate/methionine cycle — community reports of homocysteine effects in MTHFR-variant carriers (anecdotal; from a physician YouTube explainer — treat as unverified). Cancer claim ("cancer risk") is unsupported; absence of data, not evidence of safety.

Contraindications: Pregnancy/breastfeeding; pre-existing cardiac conditions (palpitation reports); anyone seeking treatment for diabetes/obesity (no evidence of benefit — BSCG).

Interactions: Theoretical AMPK-pathway overlap (metformin, berberine); MTHFR/folate-related supplements (unverified community reports).

What we publish: USADA quote verbatim; "no completed clinical trials" headline; separation of anecdote from evidence; CB4211 analog data clearly labelled as analog.

Sources: usada.org (What is MOTS-c); bscg.org; alzdiscovery.org ADDF report; innerbody.com; clinicaltrials.gov NCT07505745; e-dmj.org review.

2.6 Tesamorelin

Identity: Stabilised GHRH (GRF 1–29) analogue. Approved drug (Egrifta, Egrifta SV/WR) for reduction of excess abdominal fat in HIV lipodystrophy. VALEN LABS sells it strictly as a research chemical; every human-use framing is off-label.

Evidence base: The best-documented of the GH-axis SKUs: Phase 3 RCTs (26 weeks) + 52-week extension in HIV lipodystrophy; 12-week RCT in type 2 diabetes; long-term safety data available. Generally well tolerated; modest IGF-1 rise; no clinically significant glucose worsening in diabetic RCT.

Side effects table:

| Effect | Frequency/Notes | Source | |---|---|---| | Injection-site reactions (erythema, pruritus, swelling, pain) | Common, mild–moderate | Drugs.com; Synapse; NATAP 52-wk | | Joint pain / arthralgia | Reported; GH-class effect | Drugs.com; Innerbody | | Peripheral oedema (swelling hands/ankles/feet) | GH-class fluid retention | Drugs.com; Hormone Health | | Muscle pain / stiffness | Reported | Drugs.com; Hormone Health | | Nausea, fatigue | Early-treatment, transient | Hormone Health | | Hypersensitivity reactions (rash, itching; rarely anaphylactoid) | Rare; emergency signs = hives, dyspnoea, facial swelling | Drugs.com; Synapse | | Worsening glucose tolerance | Class concern; 52-wk HIV data showed no clinically significant change; T2D RCT showed no worsening vs placebo | PLOS ONE; NATAP | | Carpal-tunnel-like symptoms, fluid retention (higher doses) | GH-class | Class-effect literature |

Serious risks: IGF-1 elevation is mitogenic — active malignancy is an absolute contraindication (Peptides Lab UK; Drugs.com). Pituitary pathology contraindicated.

Contraindications (absolute): Active malignancy; pituitary tumour / pituitary surgery / head irradiation; pregnancy/breastfeeding; hypersensitivity. (Relative): diabetes/impaired glucose tolerance, significant cardiovascular disease, chronic oedematous conditions (Peptides Lab UK).

Interactions: Glucose-lowering drugs (monitor); diuretics/corticosteroids (fluid balance); any GH/IGF-1 modulating agent.

What we publish: Approved-drug AE profile + explicit "off-label use has no approved safety evaluation" + contraindication list.

Sources: drugs.com/tesamorelin.html; PLOS ONE 0179538; NATAP 52-week study; Peptides Lab UK; Innerbody; Synapse Patsnap; Hormone Health Inverness.

2.7 CJC-1295 (no DAC) & Ipamorelin

(Sold as separate SKUs; combined here because they are normally researched as a stack. Cards below cover each.)

2.7a CJC-1295 (no DAC)

Identity: GHRH analogue (modified GRF 1–29). "No DAC" = no Drug Affinity Complex → short half-life, more physiological GH pulses than the DAC version. Acts at the GHRH receptor.

Evidence base: No approved status; limited formal human safety data for the research-grade molecule. FDA (via compounding safety communications) warns on the DAC form re "increased heart rate and systemic vasodilatory reaction" including flushing, warmth, transient hypotension (Innerbody CJC-1295).

Side effects table:

| Effect | Notes | Source | |---|---|---| | Injection-site reactions | Most common | Rite Aid; JoinMIDI | | Flushing, warmth, transient hypotension | Class/known GHRH-analogue effect (esp. DAC form per FDA) | Innerbody; Rite Aid | | Headache | Common | Rite Aid; Perfectb | | Water retention / oedema / carpal-tunnel-like symptoms | GH-class | Rite Aid; JoinMIDI; Superpower | | Increased appetite (mild) | Ghrelin-axis overlap with secretagogues | Superpower | | Joint/muscle pain, nausea, appetite changes | Reported | JoinMIDI | | Vivid dreams (first weeks) | Reported | Perfectb | | Raised blood sugar / insulin resistance | GH-class; monitor fasting glucose/HbA1c | Rite Aid; Superpower |

Serious risks: Elevated IGF-1 above age-adjusted range with long use; glucose dysregulation; fluid retention. Red-flag symptoms requiring urgent care: severe headache, vision changes, shortness of breath, chest pain, rapid swelling, fainting (JoinMIDI).

Contraindications: Active cancer or history (GH/IGF-1 mitogenic); pregnancy/breastfeeding; pituitary disorders; diabetic retinopathy; children/adolescents (epiphyseal growth plates).

Interactions: Glucose-lowering medications; diuretics; corticosteroids; other GH-axis agents.

2.7b Ipamorelin

Identity: Synthetic pentapeptide GH secretagogue (GHSR-1a/ghrelin-receptor agonist), developed for high GH selectivity with minimal cortisol/prolactin/ACTH effects vs older GHRPs (GHRP-2/6).

Evidence base: No approved human indication; limited formal trials of the research molecule; class literature from GHRP development.

Side effects table:

| Effect | Notes | Source | |---|---|---| | Injection-site redness/swelling | Common | Superpower; Huddle | | Flushing, headache | Transient | Superpower; Rite Aid (stack) | | Water retention | GH-class | Superpower | | Mild nausea / lightheadedness (first week) | Reported in a minority | Huddle | | Increased appetite | Class effect (ghrelin); less pronounced than GHRP-2/6 | Superpower | | Vivid dreams | Reported | Perfectb (stack) |

Serious risks: Same GH-class set as CJC-1295 (IGF-1 overshoot, glucose, fluid retention). Sleep-apnoea caution: GH elevation can worsen upper-airway tone in susceptible individuals (Meto).

Contraindications: Active malignancy; pregnancy/breastfeeding; pituitary pathology; diabetes/ prediabetes (relative, monitor); uncontrolled CVD; sleep apnoea (relative).

Interactions: Glucose-lowering agents; other secretagogues/GHRH analogues (stacking amplifies GH effect and unknowns); any agent affecting prolactin/cortisol.

WADA: Both are prohibited S2; athletes must check the current Prohibited List (Superpower).

Sources: innerbody.com/cjc-1295-and-ipamorelin; riteaid.com/peptides/cjc-1295; superpower.com (CJC/Ipa stack guide); joinmidi.com; meto.co; springfieldptwellness.com; huddlemenshealth.com; perfectb.com.

2.8 GHK-Cu (Copper Tripeptide-1)

Identity: GHK (glycyl-histidyl-lysine) complexed with Cu²⁺; decades of topical cosmetic use (wound healing, collagen/GAG synthesis, anti-ageing). Injectable research use is newer.

Evidence base: Extensive cell/animal literature and human topical cosmetic history (PMC6073405: "used in anti-aging and cosmetic products in humans for decades without any adverse effects"). Injectable human data: limited.

Side effects table:

| Effect | Notes | Source | |---|---|---| | Local redness/tingling/irritation (topical, high conc.) | Common, mild | Empire Medical; Westlake Derm; Lesielle | | Acne-like breakouts (acne-prone skin) | Reported | Westlake Derm | | Temporary blue/green skin discolouration | Copper ions; fades in hours | Lesielle | | Injection-site reactions (injectable) | Expected for any sub-Q peptide | First Compounding | | Allergic reactions (rash, swelling) | Rare | Superpower consent | | "Copper peptide uglies" (flushing, breakouts) | Community term; anecdotal, rare | Reddit r/30PlusSkinCare PSA |

Serious/theoretical risks: FDA: "compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities" (quoted in Superpower's informed-consent page). Copper overload/toxicity at excessive doses (Wilson's disease and copper-metabolism disorders are the classic risk group). Topical antagonism with vitamin C, retinoids, AHAs (oxidation/chelation — cosmetic-formulation issue, not systemic).

Contraindications: Pregnancy/breastfeeding; copper-metabolism disorders (Wilson's disease, etc.); known copper allergy/sensitivity; hemochromatosis-type iron/copper loading conditions (caution).

Interactions: Topical vitamin C/retinoids/AHAs (formulation); oral copper supplements (theoretical overload); penicillamine/trientine (copper chelators).

What we publish: Cosmetic-safety history + FDA immunogenicity quote + copper-overload caution.

Sources: firstcompounding.com; westlakedermatology.com; superpower.com (informed consent); PMC6073405; empiremedicaltraining.com; lesielle.com; Reddit r/30PlusSkinCare (anecdotal).

2.9 Tirzepatide

Identity: Dual GIP/GLP-1 receptor agonist. Approved drug (Mounjaro — T2D; Zepbound — obesity). Any peptide-shop vial is an unlicensed copy of an approved medicine — highest regulatory scrutiny (see §5.3).

Evidence base: Very large trial program (SURMOUNT, SURPASS; >10,000 participants). Cancer incidence in trials comparable to control over 72 weeks.

Side effects table:

| Effect | Frequency/Notes | Source | |---|---|---| | Nausea | Most common GI AE | Fella Health; Drugs.com | | Diarrhoea, vomiting, constipation, abdominal pain | Common, dose-dependent | Fella; Drugs.com | | Decreased appetite | Expected effect | Drugs.com | | Injection-site reactions | Common | Class data | | Hypoglycaemia | Mainly when combined with insulin/sulfonylureas | Class data | | Pancreatitis (incl. rare necrotising/fatal) | Class risk; strengthened MHRA warnings | MHRA Drug Safety Update | | Gallbladder disease (cholelithiasis, cholecystitis) | Class risk | Class data | | Thyroid C-cell tumours (rodent) | Boxed warning; human relevance unknown | FDA PI via Fella/Drugs.com |

Serious risks — boxed warning: Rodent studies showed dose-dependent thyroid C-cell tumours incl. medullary thyroid carcinoma → contraindicated in personal/family history of MTC or MEN2. Counsel on symptoms: neck mass, dysphagia, dyspnoea, persistent hoarseness. Human relevance undetermined; no clear increase in MTC in trials to date, but exposure/follow-up limited (Drugs.com).

Contraindications: Personal/family history of MTC or MEN2; pregnancy (discontinue; weight-loss during pregnancy is contraindicated); hypersensitivity; severe GI disease (caution); history of pancreatitis (caution).

Interactions: Delayed gastric emptying → may alter absorption of oral medications (incl. contraceptives — counsel); insulin/sulfonylureas → hypoglycaemia (dose reduction needed); alcohol (GI load).

What we publish: Boxed-warning text summary, GI AE table, MTC/MEN2 contraindication, "unlicensed copy of an approved medicine" statement.

Sources: fellahealth.com; drugs.com/medical-answers/tirzepatide-cause-cancer; PMC11050669; roswellpark.org; cancernetwork.com; gov.uk MHRA Drug Safety Update.

2.10 Semaglutide

Identity: GLP-1 receptor agonist. Approved drug (Ozempic/Wegovy/Rybelsus — T2D/obesity). Same unlicensed-copy status warning as Tirzepatide.

Evidence base: Very large trial program (STEP, SUSTAIN); decades of GLP-1-class safety data.

Side effects table:

| Effect | Frequency/Notes | Source | |---|---|---| | Nausea | ~44% at 2.4 mg in STEP-1 | Second Nature | | Vomiting | ~25% | Second Nature | | Diarrhoea, constipation, abdominal pain | Common | PMC11050669; Roswell Park | | Injection-site reactions | Common | Class data | | Hypoglycaemia | With insulin/sulfonylureas | Class data | | Pancreatitis (incl. rare necrotising/fatal) | Class risk; MHRA strengthened warnings | MHRA DSU | | Gallbladder disease | Class risk | Roswell Park; MHRA | | Vision changes (diabetic retinopathy) | Reported; monitor | Roswell Park | | Increased heart rate | Reported | Roswell Park | | Depression / suicidal ideation | Signal monitored; current evidence shows no significant increase in depression/anxiety/suicidality incidence | PMC11889434; Roswell Park | | Thyroid C-cell tumours (rodent) | Boxed warning; human relevance unknown | PMC11050669; Roswell Park |

Serious risks — boxed warning: same MTC/MEN2 contraindication as Tirzepatide (FDA boxed warning on Ozempic/Wegovy/Rybelsus). Differentiated thyroid cancers (papillary/follicular/Hürthle) are NOT a contraindication (Clayman Thyroid Center via CancerNetwork).

Contraindications: Personal/family history MTC or MEN2; pregnancy; hypersensitivity; caution in pancreatitis, severe GI disease, retinopathy.

Interactions: Same as class: delayed gastric emptying → oral-med absorption; hypoglycaemia with insulin/sulfonylureas; alcohol.

What we publish: Boxed warning + MTC/MEN2 + GI table + psychiatry-signal status (no proven causal increase) + MHRA pancreatitis warnings.

Sources: PMC11050669; PMC11889434; roswellpark.org; cancernetwork.com; secondnature.io; gov.uk MHRA Drug Safety Update.

2.11 Retatrutide

Identity: Triple GIP/GLP-1/glucagon receptor agonist, Eli Lilly, investigational — NOT FDA approved (as of July 2026 per Drugs.com). Peptide-shop vials are unlicensed copies of an investigational molecule.

Evidence base: Phase 2 (NEJM 2023, up to 24.2% weight loss @ 12 mg/48 wk) and Phase 3 (TRIUMPH series) trials. Long-term safety incomplete.

Side effects table:

| Effect | Frequency/Notes | Source | |---|---|---| | Nausea | ~40–43% at 12 mg (TRIUMPH-1/-4); most common AE | Ro; Second Nature; NEJM | | Diarrhoea | ~32–33% at 12 mg | Second Nature; PMC12026077 | | Constipation | ~26% at 12 mg | Second Nature; GoodRx | | Vomiting | ~21–25% at 12 mg | Second Nature; NEJM | | Dysesthesia (skin sensation changes) | ~20.9% at 12 mg — distinctive for this molecule | Second Nature; GoodRx | | Heart-rate increase | ~6.7 bpm @ 12 mg — larger than other GLP-1s | Second Nature | | Decreased appetite | Expected effect | GoodRx | | Headache, dizziness, fatigue, injection-site reactions | Class-type events | GoodRx | | Weight-loss-related bone loss | Concern flagged esp. menopausal women | UC Health |

Serious risks: Class GLP-1 risks apply (pancreatitis, gallbladder disease, GI). Heart-rate increase larger than comparators — relevant for cardiac history. ~11.3% discontinued at 12 mg for AEs vs 4.9% placebo (TRIUMPH-1).

Contraindications: Same as GLP-1 class (MTC/MEN2 family history per class labelling once approved; currently investigational); pregnancy; hypersensitivity.

Interactions: Same class set (gastric emptying, hypoglycaemia with insulin/sulfonylureas).

What we publish: "Investigational — no approval" banner; distinctive AE profile (dysesthesia, HR increase); class-risk table.

Sources: drugs.com/history/retatrutide.html; NEJMoa2301972; PMC12026077; goodrx.com; secondnature.io; ro.co; midwestmindandbodyhealthcare.com; uchealth.org.

2.12 TB-500 (Thymosin β4 fragment, 17-AA)

Identity: Synthetic fragment (often acetylated, ~17 aa) of thymosin β4 (Tβ4). NOTE: there is no universally standardised "TB-500" sequence across vendors — identity testing is essential.

Evidence base: Full-length Tβ4 has Phase I/II human data (wound healing, corneal); the 17-AA fragment has no published Phase 1/2 human safety studies (Superpower). Preclinical tox: no organ toxicity, mutagenicity, carcinogenicity, or reproductive-toxicity signals in standard assessments (Peptides Lab UK). Community-reported AE rates (headache 10–15%, injection-site reactions 10–20%, lethargy during loading) — label as anecdotal (Peptides Explorer).

Side effects table:

| Effect | Notes | Source | |---|---|---| | Injection-site irritation (redness, swelling, tenderness) | Common, resolves within ~a day | MoonshotMP; Innerbody | | Headache | Community-reported ~10–15% | Peptides Explorer | | Lethargy / temporary fatigue | Common during loading phase | MoonshotMP; Peptides Explorer | | Head rush / lightheadedness (systemic vasodilation) | Brief | Peptides Explorer; MoonshotMP | | Fever, blistering at site, muscle aches, rash, vomiting, severe itching, hives | Rare but more serious; stop and seek care | Innerbody |

Serious/theoretical risks: Pro-angiogenic and cell-migration mechanism → theoretical tumour- support concern. No direct evidence that exogenous TB-4 promotes tumour growth in published animal models (Goldstein & Kleinman 2010, via Peptides Explorer), but active/recent cancer is treated as a contraindication by every clinician source. FDA lists the Tβ4 fragment (LKKTETQ) among bulk drug substances that may present significant safety risks in compounding (via MDPI Tβ4 review). WADA prohibited (S2).

Contraindications: Pregnancy/breastfeeding (Tβ4 has roles in embryonic development); active/suspected cancer; bleeding disorders (theoretical); concurrent anticoagulant use (relative, GlobalRPH).

Interactions: Anticoagulants (theoretical); no formal interaction data exists.

What we publish: "Fragment ≠ full-length Tβ4 — different safety dataset" framing; anecdote-vs- evidence split; theoretical cancer caution.

Sources: peptideslabuk.com; moonshotmp.com; peptidesexplorer.com; superpower.com (TB-500); globalrph.com; innerbody.com (TB4/TB-500); MDPI 2076-3417/16/12/6202.

2.13 BPC-157 (Body Protection Compound)

Identity: Pentadecapeptide derived from human gastric juice; research interest in GI, tendon/ ligament, and tissue-repair models.

Evidence base: Extensive animal literature (rats/mice); only ~3 completed human studies (e.g., 2024 intravesical cystitis study: no reported side effects in 12 participants). A 2015 Phase I trial (NCT02637284, 42 healthy volunteers) was started but results were never published (MDPI). Animal data: no toxic/lethal threshold, no teratogenic/genotoxic/anaphylactic signals (PMC12446177).

Side effects table:

| Effect | Notes | Source | |---|---|---| | Injection-site reactions | Most commonly reported (all peptides) | Rite Aid; Healthymale | | Lightheadedness, fatigue, nausea | Reported in users; mild | Rite Aid | | Brain fog, dizziness, anxiety changes, sleep issues, unusual pain | Anecdotal (YouTube/community) — unverified | YouTube review | | Serious AEs in human studies | None reported to date | PMC12446177 |

Serious/theoretical risks: In-vitro-based theoretical concerns: pathological angiogenesis, overproduction of nitric oxide, toxic-metabolite formation; FAK–paxillin pathway activation that could in theory promote metastasis (Ortho & Wellness). These are hypotheses from mechanism, NOT observed human outcomes — but they are why cancer history is a caution. WADA banned; illegal to possess without prescription in Australia (TGA); not FDA-approved anywhere.

Contraindications: Pregnancy/breastfeeding; active cancer or significant cancer risk factors; active GI bleeding (relative — Peptides Explorer); bleeding disorders/anticoagulants (relative, GlobalRPH).

Interactions: No formal interaction studies. Theoretical: anticoagulants/antiplatelets (bleeding modulation), NSAIDs, anything affecting angiogenesis. State as "no data".

What we publish: Animal-data strength + "3 human studies" honesty + theoretical-cancer-caution box + "long-term human safety data does not exist" (Examine.com).

Sources: riteaid.com/peptides/bpc-157; pmc.ncbi.nlm.nih.gov/articles/PMC12446177; mdpi.com/1424-8247/18/2/185; orthoandwellness.com; examine.com/supplements/bpc-157; healthymale.org.au; globalrph.com.

2.14 Semaglutide/Tirzepatide cross-reference for GLOW-adjacent SKUs

(No additional SKU — see cards 2.9/2.10. This slot is a placeholder to keep the SKU count unambiguous: 14 SKUs = GLOW, SS-31, Kisspeptin, NAD+, MOTS-c, Tesamorelin, CJC-1295, Ipamorelin, GHK-Cu, Tirzepatide, TB-500, Semaglutide, BPC-157, Retatrutide.)

3. INJECTION / HYGIENE RISKS

3.1 Why injection risk is universal and serious

Every injectable SKU carries the standard parenteral-administration risk set, independent of the molecule: infection (bacterial/fungal), abscess, sepsis, allergic reaction, nerve/vessel injury, dosing error, and air embolism (self-injection "air shot" risk is cited by ColumbiaDoctors and The Guardian). Health Canada's public warning is the clearest regulator statement: unauthorized peptide drugs "may lead to infections, allergic reactions, and other serious complications".

3.2 Risk drivers specific to research peptides

  1. Not manufactured under GMP for human use. No sterile fill-and-finish requirement, no regulatory batch release. Sterility is a COA claim, not a guarantee.
  2. Reconstitution is an open manipulation. Lyophilised powder + bacteriostatic water + syringe = contamination opportunity at every step. SwissChems explicitly notes bacteriostatic water is not included and must be sourced separately — the industry norm, and a risk point.
  3. No pharmacist/physician check. The person drawing the dose is the buyer. Dosing errors (unit conversion mcg/mg, insulin-syringe marks) are a documented community failure mode.
  4. Cold-chain fragility. Peptides degrade with heat/light; degraded product ≠ same safety profile (aggregates are an immunogenicity risk — FDA note on GHK-Cu).
  5. Repeated daily dosing (typical for many protocols) multiplies local-tissue exposure — injection-site reactions dominate every trial dataset for exactly this reason (SS-31 MMPOWER, Tesamorelin trials, CB4211).

3.3 Community best-practice hygiene guidance (for research-handling pages)

From the Peptide Protocol Wiki safety guide (community harm-reduction standard) plus clinical sources:

  • Rotate injection sites; do not reuse the same site daily.
  • Use sterile single-use needles/syringes; never reuse or share.
  • Wipe vial septum with alcohol; allow refrigerated reconstituted peptide to reach room temperature before drawing (reduces injection pain and aggregation).
  • Use proper aseptic technique; dispose of sharps in approved containers.
  • Discard reconstituted vials past their stated in-use expiry (typically days–weeks refrigerated, per product COA).
  • Inspect each vial before use: cloudiness, particles, off-colour, broken seal → discard.
  • Seek medical attention for: spreading redness, heat, swelling, fever, chills, pus, hives, facial swelling, difficulty breathing.

Serious-infection red flags (seek care immediately): fever/chills after injection, spreading erythema, severe pain, systemic allergic signs (hives, angioedema, dyspnoea), hypotension.

Sources: canada.ca (Health Canada warning); columbiadoctors.org; theguardian.com (2026-04-04); peptideprotocolwiki.com/learn/safety; swisschems.is/faqs; riteaid.com; healthymale.org.au.

4. ENDOTOXIN / CONTAMINATION & TESTING RATIONALE

4.1 What endotoxin is and why it matters

Endotoxins are lipopolysaccharides (LPS) from the outer membrane of gram-negative bacteria. They are extremely stable, survive autoclaving/filtration/gamma irradiation/chemical sterilisation, and persist after the bacteria that produced them are dead. A sample that passes sterility testing can still fail endotoxin testing — the two are distinct compendial tests and both belong on a complete COA (American Peptides; Thermo Fisher). Endotoxin activates TLR4 → NF-κB → TNF-α/IL-6, which (a) confounds any inflammation-related assay and (b) can cause fever, chills, and in severe exposure septic-shock-type reactions in vivo (Thermo Fisher; The Guardian citing scientists).

4.2 Regulatory limits (reference values)

  • Pharmacopoeial injectable limit context: USP <85> (LAL) / <86> (rCR) govern bacterial-endotoxin testing of pharmaceutical products (Eagle Analytical).
  • Typical drug-product limits are in the low single-digit EU/kg-dose range; GenScript's research-grade "Endotoxin Control" service guarantees <0.01 EU/µg.
  • Community RUO benchmark scale (Imperial Peptides UK): <5 EU/vial = excellent; 5–10 = high- quality; 10–30 = typical general RUO; >30 = may affect sensitive assays.
  • Finnrick's vendor-flag scale: <5 EU/vial = normal baseline; 5–40 = detectable contamination, evaluate; >40 = unacceptable quality control failure.
  • Published grey-market reality: The Peptide List's 2026 investigation of 10 gray-market peptide samples: 3 failed; examples — BPC-157 89.1% purity / 4.5 EU/mg endotoxin / lead 0.8 ppm; CJC-1295 78.9% purity / 6.4 EU/mg / lead 1.2 ppm; GHK-Cu 83.2% purity, free copper, excess heavy metal. Tier-4 products averaged ~75% purity, 8+ EU/mg, plus lead and mercury, vs 503B pharmacy product at 98–99%+ purity and <0.5 EU/mg. A Jesse Morse tweet (2025) reported ~63% of tested samples contained detectable endotoxin. Janoshik (Czech Republic) tests ~5,000 samples/month (The Guardian, 2026-04-06).

4.3 What a complete research COA should contain

From Peptide Hackers' third-party testing guide + Finnrick + Imperial:

  1. Chromatographic purity (HPLC/LC-MS) — target compound vs impurities.
  2. Molecular identity (MS) — observed vs theoretical mass; confirms it is the labelled compound, not a lookalike.
  3. Peptide content (actual peptide mass vs total powder) — drives accurate dosing.
  4. Endotoxin level (LAL or rFC/rCR), in EU/mg or EU/vial.
  5. Sterility (USP <71> or equivalent) — absence of viable microorganisms.
  6. Heavy metals (ICP-MS) — lead, mercury, arsenic, cadmium; grey-market failures documented.
  7. Batch number + analysis date — purity is a snapshot; old COAs drift (storage/handling).
  8. Impurity profile — deletion sequences, truncations, residual protecting groups, aggregates/ dimers (mass spec fingerprinting).

4.4 VALEN LABS testing policy (commitment we publish)

  • Every batch third-party tested (HPLC purity, MS identity, peptide content, LAL endotoxin, USP sterility, heavy metals) at an independent lab (Janoshik-style service).
  • COA per batch, public, linked from the product page, with batch number and analysis date.
  • Endotoxin quantified (EU/mg or EU/vial) — not a pass/fail checkbox.
  • Batch traceability retained for regulatory/inspection purposes (per Wallid compliance checklist).
  • Any batch failing identity, sterility, or exceeding our endotoxin threshold is quarantined and never shipped.

Sources: americanpeptides.us; imperialpeptides.co.uk; finnrick.com; thermofisher.com (Endotoxins 101); eagleanalytical.com (USP <85>/<86>); genscript.com; peptidehackers.com; thepeptidelist.com; janoshik.com; theguardian.com (2026-04-06); x.com/DrJesseMorse (63% statistic, secondary).

5. LEGAL & RUO FRAMING

5.1 What "Research Use Only" actually is

RUO is a product classification used across the chemical-supply industry: the product is labelled and contracted for laboratory research, carries no claim of safety or efficacy for any other use, and is not manufactured/registered as a medicine, food, cosmetic, or medical device. The classification exists in both US (FDA/chemical-supply practice) and EU contexts (research chemicals falling outside the medicinal-product definition). (Sources: Precisely Peptides, Peptide Warehouse, INTRA|V, CertaPeptides.)

What the disclaimers actually do — the honest version:

  • ✅ They establish contractual terms (purpose restriction, buyer representations, indemnification) between supplier and buyer.
  • ✅ They support regulatory classification under the "presentation" limb — a product sold without therapeutic presentation is less likely to be classified as a medicine (EU Directive 2001/83/EC Art 1(2), presentation limb; CertaPeptides).
  • ❌ They are not a legal shield for actual human use. FDA warning letters (SwissChem, Dec 2024) show that marketing "research use only" while your site/socials present human use, dosing, or benefit claims = the label is disregarded and the product is treated as an unapproved drug.
  • ❌ They do not override the substance's characteristics — the EU caveat: "a 'research use only' sticker does not override the substance's actual characteristics" and borderline products are assessed case-by-case by national authorities (CertaPeptides).
  • ⚖️ Case-law note: for a disclaimer to have any contractual effect it must be clear, conspicuous, and unambiguous (McCullough v. Zimmer, Inc., cited by Peptidelaws.com).

5.2 Quoted vendor disclaimers (the industry phrasing)

Direct Peptides (UK/EU) — Terms & Conditions:

"Products sold through Direct Peptides are intended strictly for RESEARCH purposes only and by accepting Direct Peptides's terms and conditions set out herein you are agreeing to their use in this manner. These products are NOT for HUMAN CONSUMPTION. … Products are not classed as medicines or drugs that have been approved by the FDA (where customers reside in the United States) or by the MHRA (where customers reside in the United Kingdom) to prevent, treat, diagnose, mitigate or cure any medical condition or disease."

Direct Peptides — FAQ:

"DISCLAIMER: All products listed on this website and provided through Direct Peptides are intended for laboratory research and development purposes only. The products listed on this website are not for human or animal consumption or ingestion of any kind. … Our products are sold on the understanding that they are exclusively for research purposes only. They should never be used for the treatment of any medical condition, deficiency or disease or be added to food for human consumption."

Direct Peptides — Terms of Service (directpeptides.com/terms):

"Direct Peptides provides research-grade materials intended exclusively for laboratory research purposes. All products are not for human or animal consumption, clinical use, diagnostic use, or any other application that would violate local, state, or federal law. These materials have not been evaluated or approved by the FDA or any comparable regulatory authority. … Direct Peptides is a chemical supplier. Direct Peptides is not a compounding pharmacy or chemical compounding facility as defined under 503A … or an outsourcing facility as defined under 503B … All products are sold for research, laboratory, or analytical purposes only, and are not for human consumption."

SwissChems (US) — Terms & Conditions:

"All products are sold for laboratory research use only, not for human or veterinary use. Purchasers must be 21 or older. By completing a purchase, the buyer accepts full liability for handling and use, and indemnifies SwissChems from all related claims. … Research chemicals are not dietary supplements and are not approved for human or veterinary use. The following uses are not permitted: Oral consumption; Human or animal injections; Drugs and foods; Animal or human cosmetics; Animal or human consumption; Commercial use; Any use that violates applicable local laws."

SwissChems — FAQs:

"All SwissChems products — including SARMs, peptides, nootropics, bioregulators, and PCT compounds — are supplied exclusively for laboratory and in vitro research purposes. These compounds are not approved by the FDA for human consumption and are not intended for personal use under any circumstances. … SwissChems does not provide usage or dosage guidance, as doing so would be inconsistent with the research-only designation of these compounds."

CleanPeptides.eu (NL/EU) — observed site gate:

"Our products are intended for research purposes only. Please follow the legal guidelines that apply in your country." — followed by an age gate ("Are you 18 or older?") and a purpose gate ("Will these products be used for research purposes only? — I confirm") before site access, plus cookie-consent per EU ePrivacy/GDPR.

Precisely Peptides — Research Use Disclaimer:

"All products sold by Precisely Peptides are intended exclusively for legitimate in-vitro scientific research purposes by qualified researchers aged 18 and older. These products are NOT intended for: [human consumption; clinical or diagnostic procedures; therapeutic, cosmetic, or household use; veterinary or animal applications] … Precisely Peptides operates exclusively as a chemical supplier of research-grade reference materials classified as Research Use Only (RUO)."

Peptide Warehouse — Legal Disclaimer:

"All products sold by Peptide Warehouse are designated strictly for laboratory research use only. Our products are not intended for: Human consumption; Clinical or diagnostic procedures; Therapeutic, cosmetic, or household use; Veterinary or animal applications. Any use outside lawful laboratory research is strictly prohibited. … You must be 21+ to access this website."

Pure Health Peptides — Disclaimer:

"All products sold by Pure Health Peptides LLC are intended for laboratory and research purposes only. They are not for human consumption, veterinary use, or medical applications. You must be 21 years or older to purchase. Misuse of these products is strictly prohibited."

5.3 EU regulatory framework — the boundaries

Medicinal-product definition (Directive 2001/83/EC, Art 1(2)) — the hinge for the whole industry in the EU:

  • By presentation: any substance "presented as having properties for treating or preventing disease in human beings."
  • By function: any substance that "may be used in or administered to human beings either with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis."

A peptide sold strictly as a research chemical — labelled "not for human consumption", no therapeutic claims, intended for laboratory use — generally falls outside the presentation limb (CertaPeptides). Two caveats: (1) classification turns on presentation + composition + intended use together; a sticker does not override actual characteristics; (2) advertising rules (Art 86–87) prohibit advertising any medicine without marketing authorisation — so research compounds must never be promoted with human-dosing protocols, outcomes, or disease claims.

GLP-1 elevated scrutiny: semaglutide, tirzepatide, liraglutide are active substances in authorised medicines across the EU/UK → unlicensed copies map directly onto the medicinal-product definition; regulators and customs apply markedly higher scrutiny (CertaPeptides; MHRA enforcement incl. seizures of fake semaglutide pens and closure of an illegal GLP-1 facility). This affects VALEN LABS directly: our Semaglutide, Tirzepatide, and Retatrutide SKUs must carry the strictest scientific-only framing in the catalogue.

Medical-device boundary (EU MDR 2017/745): peptides as such are not medical devices; MDR excludes medicinal products within Directive 2001/83/EC (MDR Art 1(8)). A product crosses into device territory only if it is a device (e.g., an injector pen, a needle system) claiming a medical purpose. A brand-only peptide shop selling lyophilised powder does not sit in the MDR device class — but any accessory we ship (syringes, pens) that claims a medical purpose would. Verify exact device classification with counsel before bundling hardware.

Non-EU territories relevant to us:

  • Serbia: outside the EU; national medicines law (Zakon o lekovima i medicinskim sredstvima) and the medicines agency ALIMS govern medicinal products. Research-chemical classification follows the same presentation/function logic in principle, but Serbian law is separate from the EU Directives — confirm classification, import rules, and advertising constraints with Serbian counsel before shipping into Serbia. (No public source summarised here covers Serbia; treat as to-verify.)
  • Switzerland: Swissmedic, Therapeutic Products Act (HMG/TPA); inbound shipments cross a customs border; Swissmedic authorisation required for medicinal products (CertaPeptides).
  • UK: MHRA post-Brexit regime; active GLP-1 enforcement; UK-bound shipments face import controls (CertaPeptides; GOV.UK).

GDPR / e-commerce compliance notes for a brand-only shop (EU + Serbia customers):

  • GDPR applies to processing of EU-resident customers' personal data even if the shop is outside the EU (GDPR Art 3(2) territorial scope). For a Serbia-based shop selling into the EU, GDPR compliance is required for EU customers; Serbia has its own data-protection law (Zakon o zaštiti podataka o ličnosti) aligned with GDPR.
  • Required elements: privacy policy, cookie-consent banner (ePrivacy — as CleanPeptides runs), lawful basis for marketing (opt-in consent), data-minimisation (age gate = minimal data), DPO appointment only if core activities involve large-scale monitoring/special-category data (unlikely for a peptide shop — verify), and a data-processing register.
  • Payment data: use PCI-DSS-compliant payment processors; never store card data.
  • Consumer rights: EU Consumer Rights Directive 2011/83/EU gives 14-day withdrawal; the exception for goods unsealed "for health protection or hygiene reasons" applies to opened peptide vials (CleanPeptides' return policy operationalises exactly this).
  • The lesson from the FDA SwissChem letter for EU shops: regulators look at the whole presentation — website copy, social media, reviews, customer support replies — not just the disclaimer page. VALEN LABS must keep human-use language out of every surface, not only the legal pages.

Sources: certapeptides.com (EU country-by-country); eur-lex.europa.eu (Directive 2001/83/EC); fda.gov SwissChems warning letter; jdsupra.com (five warning letters analysis); peptidelaws.com; direct-peptides.com (terms/faqs); swisschems.is (term-conditions/faqs); cleanpeptides.eu (gate + return policy); preciselypeptides.com; peptide-warehouse.com; purehealthpeptides.com; synthevialabs.co.uk (age-verification policy); wallid.co (compliance checklist); ck-peptides.com.

5.4 What VALEN LABS should publish (draft legal-page core)

  1. RUO banner (site-wide, all pages, above the fold):

    "FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT APPROVED AS A MEDICINE BY EMA, FDA, MHRA, SWISSMEDIC, ALIMS, OR ANY OTHER REGULATORY AUTHORITY."

  2. Purpose restriction (Terms): products are research reagents; prohibited uses enumerated (human/animal consumption, injection into any living being, clinical/diagnostic use, cosmetic use, food/drug application); buyer represents lawful research use; buyer indemnifies VALEN LABS against misuse.
  3. No-claims clause: no statement on the site diagnoses, treats, cures, or prevents any disease; no human dosing or outcome content; no comparison to approved medicines as alternatives.
  4. Not-a-pharmacy clause (mirroring Direct Peptides): "VALEN LABS is a chemical supplier, not a compounding pharmacy or outsourcing facility."
  5. Age/purpose gate: 18+ for EU/Serbia traffic; 21+ for US traffic; mandatory "I confirm research use only" checkbox at entry and checkout.
  6. COA commitment: every batch third-party tested; COA linked per product; batch traceability.
  7. Safety pages: universal cautions (§1), per-peptide cards (§2), injection hygiene (§3), endotoxin/testing explainer (§4).
  8. Referral language: "If you are considering any peptide for effects on your own body, consult a licensed physician. VALEN LABS does not provide medical advice."
  9. GLP-1 special framing: the three GLP-1-class SKUs carry an extra banner: "Active substance of an authorised medicine. Research-grade chemical only; not a substitute for prescribed treatment."

6. RESPONSIBLE SALES POLICY SPEC — VALEN LABS

Objective: sell research materials only, to researchers, with maximum defensibility under EU and Serbian law and alignment with the best practices of the vendors quoted above.

6.1 Access control

| Control | Spec | Reference | |---|---|---| | Entry age gate | 18+ (EU/Serbia), 21+ (US traffic) | CleanPeptides (18+), SwissChems/Pure Health (21+) | | Purpose confirmation | Mandatory "I confirm use for research purposes only" at site entry AND checkout | CleanPeptides; Wallid checklist | | Checkout declaration | Buyer attests: 18+/21+, lawful research use, not for human/animal consumption | Peptide Warehouse; Precisely Peptides | | No-sale signals | Block orders with personal-address-only shipping to residential zones where policy requires institutional addresses (assess per market) | Industry practice; verify legality |

6.2 Content rules (what we will and won't publish)

  • Will publish: molecular identity, research background, mechanism summaries with citations, safety cards (§2), COAs, storage/reconstitution-for-research guidance, hygiene guidance (§3), legal pages (§5.4).
  • Will NOT publish: human dosing protocols, "cycles", injection schedules for people, benefit claims for any condition, before/after human anecdotes, "peptide therapy" phrasing, comparison to prescribed drugs as alternatives, or any content that could establish intended human use. (FDA SwissChem letter is the cautionary template: intent is inferred from ALL surfaces.)

6.3 Contraindication warnings on product pages

Each SKU page carries a standardised "Do not use if" block derived from Section 2: pregnancy/breastfeeding; under 18; active or past cancer (GH-axis & angiogenic SKUs); pituitary disease (GH-axis); MTC/MEN2 family history (GLP-1 class); copper-metabolism disorders (GHK-Cu); diabetes on glucose-lowering medication (all); bleeding disorders/anticoagulants (injectables); known allergy. Plus the universal line: "No long-term human safety data exists for this compound."

6.4 Physician referral

  • Standard line on every product page and in order confirmation:

    "Research products are not for human use. If you are exploring peptides for health purposes, speak with a licensed physician; do not self-administer research chemicals."

  • FAQ answer template explaining why we cannot advise on human use (regulatory + safety), with a redirect to medical professionals.
  • No medical-advice disclaimer on every page footer.

6.5 Quality & traceability

  • Third-party COA per batch (HPLC, MS identity, content, LAL endotoxin, sterility, heavy metals); public COA per product; batch numbers on every vial label and invoice.
  • Retain batch records and customer confirmation records (retention period per local law; GDPR- compliant).
  • Adverse-event / misuse reporting channel (support email) and internal review process.

6.6 Compliance hygiene

  • Legal pages: Terms, Privacy, Refund/Return (14-day + hygiene exception), Cookie Policy, Shipping, Disclaimer, Age policy — always visible (Wallid checklist).
  • No "research chemical"/"peptide" text-trigger evasion games with payment processors; use compliant PSPs with clear business model documentation.
  • GDPR/ePrivacy: consent-based cookie banner, privacy policy, data-minimisation; Serbian DPA law compliance for Serbian customers.
  • WADA/athlete notice on performance-related SKUs (athletes must check their sport's rules).
  • Regular legal review: EU law changes (e.g., the June 2026 EMA synthetic-peptide guideline — CertaPeptides) and national lists (Serbia, EU member states) are moving targets.

6.7 KPI-style review triggers

  • Any customer-support reply that drifts into human-use advice → retrain immediately (it becomes "intended use" evidence).
  • Any influencer/UGC marketing → prohibited (same reasoning).
  • Any regulator communication → pause the affected SKU/market and involve counsel.

7. SOURCES

7.1 Per-peptide safety

  • Rite Aid — BPC-157: https://riteaid.com/peptides/bpc-157
  • PMC12446177 — BPC-157 narrative review: https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177
  • MDPI Pharmaceuticals 18(2):185 — BPC 157 review: https://www.mdpi.com/1424-8247/18/2/185
  • Ortho & Wellness — BPC-157 deep dive: https://www.orthoandwellness.com/blog/bpc-157-update-and-deep-dive-miracle-healing-peptide-or-hidden-danger
  • Examine.com — BPC-157: https://examine.com/supplements/bpc-157
  • Healthymale.org.au — BPC 157: https://healthymale.org.au/health-article/bpc157-side-effects
  • Empire Medical Training — SS-31: https://www.empiremedicaltraining.com/antiaging-regenerative-workshops/resources/peptide-therapy/ss-31
  • The Peptide Catalog — SS-31 side effects: https://thepeptidecatalog.com/articles/ss-31-side-effects
  • PMC9192202 — SS-31 kidney review: https://pmc.ncbi.nlm.nih.gov/articles/PMC9192202
  • Neurology — elamipretide dose-escalation trial: https://www.neurology.org/doi/10.1212/WNL.0000000000005255
  • PMC11816484 — elamipretide review: https://pmc.ncbi.nlm.nih.gov/articles/PMC11816484
  • Biomeme — SS-31 evidence score: https://biomeme.com/applications/wellness/peptide-evidence/ss-31
  • USADA — MOTS-c: https://www.usada.org/spirit-of-sport/what-is-mots-c-peptide
  • BSCG — MOTS-c: https://www.bscg.org/blogs/single/mots-c-peptide-benefits-safety-legal-status-and-research
  • ADDF Cognitive Vitality — MOTS-c report: https://www.alzdiscovery.org/uploads/cognitive_vitality_media/MOTS-c.pdf
  • Innerbody — MOTS-c: https://www.innerbody.com/mots-c-peptide
  • ClinicalTrials.gov — MOTS-c insulin sensitivity (NCT07505745): https://clinicaltrials.gov/study/NCT07505745
  • Drugs.com — Tesamorelin: https://www.drugs.com/tesamorelin.html
  • PLOS ONE — Tesamorelin in T2D: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0179538
  • NATAP — Tesamorelin 52-week safety: https://www.natap.org/2008/HIV/082908_02.htm
  • Peptides Lab UK — Tesamorelin contraindications: https://peptideslabuk.com/can-tesamorelin-cause-long-term-problems
  • Innerbody — Tesamorelin: https://www.innerbody.com/tesamorelin
  • Innerbody — CJC-1295 + Ipamorelin: https://www.innerbody.com/cjc-1295-and-ipamorelin
  • Rite Aid — CJC-1295: https://riteaid.com/peptides/cjc-1295
  • Superpower — CJC-1295/Ipamorelin stack: https://superpower.com/guides/cjc-1295-ipamorelin-stack
  • JoinMIDI — CJC-1295: https://www.joinmidi.com/post/cjc-1295
  • Huddle Men's Health — Ipamorelin: https://huddlemenshealth.com/blog/medical-treatments/ipamorelin
  • Meto — GH peptides guide: https://meto.co/blog/growth-hormone-peptides-guide-cjc-1295-ipamorelin-tesamorelin
  • First Compounding — GHK-Cu: https://firstcompounding.com/ghk-cu-a-comprehensive-guide-to-benefits-side-effects-and-dosages
  • Westlake Dermatology — GHK-Cu: https://www.westlakedermatology.com/trends/ghk-cu-copper-peptides-for-skin-care
  • Superpower — GHK-Cu informed consent: https://superpower.com/informed-medical-consent/ghk-cu-cream
  • PMC6073405 — GHK-Cu review: https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405
  • Fella Health — Tirzepatide & cancer: https://www.fellahealth.com/guide/tirzepatide-side-effects-cancer
  • Drugs.com — Does tirzepatide cause cancer: https://www.drugs.com/medical-answers/tirzepatide-cause-cancer-3582083
  • PMC11050669 — GLP-1 thyroid risk: https://pmc.ncbi.nlm.nih.gov/articles/PMC11050669
  • PMC11889434 — GLP-1 FAERS thyroid analysis: https://pmc.ncbi.nlm.nih.gov/articles/PMC11889434
  • Roswell Park — Ozempic & thyroid cancer: https://www.roswellpark.org/cancertalk/202409/ozempic-thyroid-cancer
  • Clayman Thyroid Center via CancerNetwork: https://www.cancernetwork.com/view/evaluating-thyroid-cancer-risk-after-glp-1-receptor-agonist-administration
  • MHRA Drug Safety Update — GLP-1 pancreatitis warnings: https://www.gov.uk/drug-safety-update/glp-1-receptor-agonists-and-dual-glp-1-slash-gip-receptor-agonists-strengthened-warnings-on-acute-pancreatitis-including-necrotising-and-fatal-cases
  • NEJM — Retatrutide Phase 2: https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
  • PMC12026077 — Retatrutide meta-analysis: https://pmc.ncbi.nlm.nih.gov/articles/PMC12026077
  • Drugs.com — Retatrutide status: https://www.drugs.com/history/retatrutide.html
  • GoodRx — Retatrutide side effects: https://www.goodrx.com/conditions/weight-loss/retatrutide-side-effects
  • Second Nature — Retatrutide side effects: https://www.secondnature.io/us/guides/weight-loss-medications/retatrutide-side-effects
  • UC Health — Retatrutide: https://www.uchealth.org/today/retatrutide-for-weight-loss
  • Peptides Lab UK — TB-500 side effects: https://peptideslabuk.com/does-tb-500-have-side-effects
  • MoonshotMP — TB-500: https://moonshotmp.com/learn/tb-500
  • Peptides Explorer — TB-500 side effects: https://peptidesexplorer.com/blog/tb-500-side-effects
  • Superpower — TB-500 guide: https://superpower.com/guides/tb-500
  • GlobalRPH — BPC-157/TB-500: https://globalrph.com/2025/11/bpc-157-and-tb-500-background-indications-efficacy-and-safety
  • Innerbody — TB4/TB-500: https://www.innerbody.com/thymosin-beta-4-and-tb-500
  • MDPI Applied Sciences 16(12):6202 — Tβ4/TB-500: https://www.mdpi.com/2076-3417/16/12/6202
  • FDA — Kisspeptin-10 on compounding risk list: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  • ClinicalTrials.gov — Kisspeptin ICF (NCT04648969): https://cdn.clinicaltrials.gov/large-docs/69/NCT04648969/ICF_000.pdf
  • PMC9898824 — Kisspeptin & sexual brain processing: https://pmc.ncbi.nlm.nih.gov/articles/PMC9898824
  • JAMA Netw Open — Kisspeptin in HSDD: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2797718
  • Peptides Lab UK — Kisspeptin-10 safety: https://peptideslabuk.com/is-kisspeptin-10-safe-for-research-purposes
  • Jana Healthcare — NAD+ side effects: https://www.janahealthcare.com/blog/nad-therapy-potential-side-effects-you-should-know
  • Helimeds — NAD+ side effects: https://www.helimeds.com/blog/nad-supplement-side-effects
  • Hubmed — NAD injection side effects: https://www.hubmeded.com/blog/nad-injections-side-effects-what-to-expect
  • Get Healthspan — NAD+ injections vs supplements: https://gethealthspan.com/research/article/nad-injections-benefits
  • Goldman Laboratories — NAD injections: https://www.goldmanlaboratories.com/blogs/blog/nad-injections
  • NAD.com — hidden dangers of NAD+: https://www.nad.com/news/are-there-hidden-dangers-to-taking-nad-supplements
  • ScienceDirect — NMN human trials update: https://www.sciencedirect.com/science/article/pii/S2161831323013595

7.2 Injection safety, contamination & testing

  • Health Canada — think twice before injecting peptides bought online: https://recalls-rappels.canada.ca/en/alert-recall/think-twice-injecting-peptides-bought-online-unauthorized-products-can-seriously-harm
  • ColumbiaDoctors — what to know about peptides: https://www.columbiadoctors.org/news/what-know-about-peptides-benefits-safety-concerns
  • The Guardian — peptides safety (2026-04-04): https://www.theguardian.com/science/2026/apr/04/what-are-peptides-safety-wellness-products-online
  • The Guardian — labs test thousands of unregulated substances (2026-04-06): https://www.theguardian.com/science/2026/apr/06/labs-testing-thousands-of-unregulated-substances-amid-peptide-craze
  • Peptide Protocol Wiki — safety guide: https://www.peptideprotocolwiki.com/learn/safety
  • American Peptides — endotoxin LAL/rFC guide: https://www.americanpeptides.us/blog/endotoxin-testing-lal-rfc-explained
  • Imperial Peptides UK — endotoxin testing: https://www.imperialpeptides.co.uk/blogs/news/endotoxin-testing-in-peptide-research
  • Finnrick — why endotoxin testing matters: https://www.finnrick.com/blog/why-endotoxin-testing-matters-for-peptides
  • Thermo Fisher — Endotoxins 101: https://www.thermofisher.com/blog/life-in-the-lab/endotoxins-101
  • Eagle Analytical — bacterial endotoxins test: https://eagleanalytical.com/bet
  • GenScript — endotoxin control service: https://www.genscript.com/peptide-endotoxin-control-analysis.html
  • Peptide Hackers — third-party testing guide: https://www.peptidehackers.com/blogs/q-a/third-party-peptide-testing-guide
  • The Peptide List — 10 peptides, 3 failed (2026): https://thepeptidelist.com/articles/peptide-lab-testing-investigation
  • Janoshik (analytical lab): https://janoshik.com
  • Vantix Bio — Janoshik endotoxin practice: https://vantixbio.com/blog/endotoxin-testing.html

7.3 Legal / RUO / compliance

  • Directive 2001/83/EC (EUR-Lex): https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02001L0083-20220101
  • CertaPeptides — EU country-by-country legal status (2026): https://certapeptides.com/blog/research-peptide-legal-status-europe-by-country-2026
  • CertaPeptides — EMA synthetic-peptide guideline explainer: https://certapeptides.com/blog/ema-synthetic-peptide-guideline-2026-eu-researchers
  • Direct Peptides — Terms & Conditions: https://direct-peptides.com/terms-and-conditions
  • Direct Peptides — Terms of Service: https://directpeptides.com/terms
  • Direct Peptides — FAQs (disclaimer text): https://direct-peptides.com/faqs
  • SwissChems — Terms & Conditions: https://swisschems.is/term-conditions
  • SwissChems — FAQs: https://swisschems.is/faqs
  • FDA — SwissChems warning letter (12/10/2024): https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/swisschems-695663-12102024
  • JD Supra — FDA five warning letters analysis: https://www.jdsupra.com/legalnews/fda-issues-five-warning-letters-to-9153032
  • Peptidelaws.com — do disclaimers provide legal protection: https://peptidelaws.com/news/research-peptide-disclaimers-do-they-provide-legal-protection
  • Precisely Peptides — Research Use Disclaimer: https://www.preciselypeptides.com/research-use-disclaimer
  • Peptide Warehouse — Legal Disclaimer: https://peptide-warehouse.com/legal-disclaimer
  • Pure Health Peptides — Disclaimer: https://purehealthpeptides.com/disclaimer
  • CleanPeptides.eu — site gate (observed), terms: https://cleanpeptides.eu/terms-and-conditions ; return policy: https://cleanpeptides.eu/return-policy ; cookie policy: https://cleanpeptides.eu/cookie-policy
  • SyntheVial Labs — Age Verification Policy: https://synthevialabs.co.uk/age-verification-policy
  • Wallid — age verification & compliance for peptide stores: https://wallid.co/blog/tpost/o3dr5pcar1-how-age-verification-protects-research-p
  • CK Peptides — red flags when buying research peptides: https://ck-peptides.com/common-red-flags-buying-research-peptides-online
  • INTRA|V — what are RUO peptides: https://www.intra-v.com/blog/what-are-research-use-only-peptides-what-you-should-know-before-buying

Appendix A — Cross-check: what changed / to verify

  1. SS-31 FDA approval (2025, Barth syndrome) — reported by Empire Medical Training & Biomeme; confirm against FDA records before publishing the "approved" claim. Grey-market SS-31 remains research-grade material.
  2. Retatrutide approval status — investigational as of Drugs.com (July 2026); re-check before publishing.
  3. Serbia — no public source in this build covers Serbian peptide-import legality; verify with Serbian counsel (ALIMS) before shipping into Serbia.
  4. EMA June 2026 synthetic-peptide guideline — referenced by CertaPeptides; read the primary document before finalising EU copy.
  5. WADA 2026 Prohibited List — verify current S2 classification per sport before publishing athlete-facing notices.
  6. Jesse Morse "63% of samples" statistic — secondary (X post); use only as anecdote, or drop.
  7. MOTS-c homocysteine/MTHFR reports — anecdotal (YouTube physician explainer); keep labelled as unverified or omit from public pages.

Appendix B — Lineage / disclaimer

This document was compiled 2026-08-09 from the sources in Section 7. It is a research/compliance reference for VALEN LABS internal use and website content. It is not medical advice, not legal advice, and not an authorisation for any human use of any product. Regulatory positions change; re-verify before publishing. All quoted disclaimers are reproduced verbatim from the cited pages.